Siemens Healthineers Hikes Outlook on Demand For Covid-Tests
(Bloomberg) -- Siemens Healthineers AG raised its guidance for the year after strong sales of coronavirus testing equipment and a rebound in demand for hospital treatment.
Revenue growth this year may be between 14% to 17%, the company said Monday in a statement. That compares with a previous projection for an 8% to 12% increase. Siemens Healthineers more than doubled its expectations for sales of rapid coronavirus test kits.
The widespread use of the tests, which allow businesses and services to reopen before vaccination programs are completed, has given Siemens Healthineers a boost amid delays in elective treatment due to the pandemic. Demand for core hospital equipment products is expected rise as health treatments returns to more normal levels, the company said.
The results were “were positive” and the new guidance “well ahead” of market estimates, Bernstein analysts led by Lisa Bedell Clive said in a note.
The raised outlook is a boost for Siemens Healthineers' management after it acquired Varian Medical Systems to gain access to devices and software used in cancer treatment. Recent developments in radiation therapy, coupled with more precise imaging, have been linked to lower death rates, a trend on which the German maker of MRI machines and laboratory equipment is keen to capitalize.
Siemens Healthineers rose as much as 2.4%, taking gains this year to 15%.
Revenue in the U.S. is expected in the coming quarters, Chief Financial Officer Jochen Schmitz said in an interview with Bloomberg TV, adding that European and Asian markets had already recovered.
The company also lifted its adjusted earnings per share outlook to between 1.90 euros ($2.28) and 2.05 euros, compared with 1.63 euros to 1.82 euros.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.